|Dr. George E. Anastassov||Founder & Chairman||595k||N/A||1963|
|Mr. John W. Huemoeller II||Pres, CEO & Director||45k||N/A||1955|
|Mr. Robert T. Malasek||CFO & Sec.||247k||N/A||1968|
|Mr. Lekhram Changoer||CTO & Director||475k||N/A||1967|
|Dr. Philip A. Van Damme D.M.D., M.D., DMD, MD, Ph.D.||Chief Medical Officer & Director||45k||N/A||1953|
Axim Biotechnologies, Inc., a biotechnology company, researches, develops, produces, and sells pharmaceutical, nutraceutical, and cosmetic products. It also engages in the extraction and purification of cannabinoids technologies based on its proprietary technologies. The company sells its products through Internet, direct-to-consumer health and wellness stores, collectives, cooperatives, and affiliate sales and master distributors. Axim Biotechnologies, Inc. was formerly known as Axim International Inc. and changed its name to Axim Biotechnologies, Inc. in July 2014. The company was founded in 2010 and is headquartered in New York, New York.
AXIM Biotechnologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.